Do analysts recommend DWTX or CYCN?

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 424.02%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor DWTX or CYCN?

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 1 mentions for Cyclerion Therapeutics. Dogwood Therapeutics' average media sentiment score of -0.39 beat Cyclerion Therapeutics' score of -2.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Cyclerion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative

Do analysts rate CYCN or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CYCN or ZYBT?

Cyclerion Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclerion Therapeutics $1.90M 10.47 -$3.53M -$1.66 N/A Zhengye Biotechnology $16.64M 4.59 -$9.98M N/A N/A

Do analysts prefer LONA or CYCN?

Athira Pharma presently has a consensus price target of $17.33, suggesting a potential upside of 129.28%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer LONA or CYCN?

In the previous week, Athira Pharma had 3 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for Cyclerion Therapeutics. Athira Pharma's average media sentiment score of 0.34 beat Cyclerion Therapeutics' score of -2.00 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cyclerion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative

Do analysts prefer CING or CYCN?

Cingulate currently has a consensus target price of $27.00, suggesting a potential upside of 429.41%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cingulate is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SPRO or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SPRO or CYCN?

In the previous week, Spero Therapeutics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Cyclerion Therapeutics. Spero Therapeutics' average media sentiment score of 0.17 beat Cyclerion Therapeutics' score of -2.00 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cyclerion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative

Cyclerion Therapeutics (CYCN) Competitors

$4.25 -0.71 (-14.31%)

As of 09/4/2026 04:00 PM Eastern

Compare

CYCN vs. DWTX, ZYBT, LONA, CING, and SPRO

Should you buy Cyclerion Therapeutics stock or one of its competitors? Cyclerion Therapeutics's main competitors and comparable companies include Dogwood Therapeutics (DWTX), Zhengye Biotechnology (ZYBT), Athira Pharma (LONA), Cingulate (CING), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cyclerion Therapeutics compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 1 mentions for Cyclerion Therapeutics. Dogwood Therapeutics' average media sentiment score of -0.39 beat Cyclerion Therapeutics' score of -2.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Cyclerion Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Negative

Dogwood Therapeutics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Dogwood Therapeutics' return on equity of -75.55% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Cyclerion Therapeutics has higher revenue and earnings than Dogwood Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Cyclerion Therapeutics	$1.90M	10.47	-$3.53M	-$1.66	N/A

Dogwood Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 424.02%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dogwood Therapeutics beats Cyclerion Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Cyclerion Therapeutics (NASDAQ:CYCN) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Cyclerion Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, indicating that its stock price is 356% less volatile than the broader market.

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Cyclerion Therapeutics' score of -2.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclerion Therapeutics	Very Negative
Zhengye Biotechnology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.6% of Cyclerion Therapeutics shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Zhengye Biotechnology's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Zhengye Biotechnology	N/A	N/A	N/A

Cyclerion Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$1.90M	10.47	-$3.53M	-$1.66	N/A
Zhengye Biotechnology	$16.64M	4.59	-$9.98M	N/A	N/A

Summary

Cyclerion Therapeutics beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Athira Pharma had 3 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for Cyclerion Therapeutics. Athira Pharma's average media sentiment score of 0.34 beat Cyclerion Therapeutics' score of -2.00 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cyclerion Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Negative

Cyclerion Therapeutics has higher revenue and earnings than Athira Pharma. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Cyclerion Therapeutics	$1.90M	10.47	-$3.53M	-$1.66	N/A

Athira Pharma has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Athira Pharma has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Athira Pharma presently has a consensus price target of $17.33, suggesting a potential upside of 129.28%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Athira Pharma beats Cyclerion Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Cingulate. Cingulate's average media sentiment score of 0.59 beat Cyclerion Therapeutics' score of -2.00 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
Cyclerion Therapeutics	Very Negative

Cingulate currently has a consensus target price of $27.00, suggesting a potential upside of 429.41%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cingulate is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclerion Therapeutics has higher revenue and earnings than Cingulate. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Cyclerion Therapeutics	$1.90M	10.47	-$3.53M	-$1.66	N/A

Cingulate has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

Cingulate has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Summary

Cyclerion Therapeutics beats Cingulate on 9 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Cyclerion Therapeutics' net margin of -170.11%. Spero Therapeutics' return on equity of 16.17% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Spero Therapeutics has higher revenue and earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$42.96M	1.64	$8.57M	$0.11	11.00
Cyclerion Therapeutics	$1.90M	10.47	-$3.53M	-$1.66	N/A

Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

In the previous week, Spero Therapeutics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Cyclerion Therapeutics. Spero Therapeutics' average media sentiment score of 0.17 beat Cyclerion Therapeutics' score of -2.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cyclerion Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Negative

Summary

Spero Therapeutics beats Cyclerion Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYCN vs. The Competition

Export

Metric	Cyclerion Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.90M	$12.27B	$7.26B	$12.91B
Dividend Yield	N/A	2.59%	2.53%	8.90%
P/E Ratio	-2.56	792.20	273.83	25.45
Price / Sales	10.47	794.57	608.03	79.09
Price / Cash	N/A	92.18	77.39	52.28
Price / Book	3.90	12.47	12.85	6.17
Net Income	-$3.53M	$2.83B	$3.49B	$350.08M
7 Day Performance	12.14%	4.03%	1.04%	-0.14%
1 Month Performance	19.72%	6.29%	5.52%	1.02%
1 Year Performance	90.58%	9.93%	24.39%	14.51%

Cyclerion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYCN Cyclerion Therapeutics	0.5148 of 5 stars	$4.25 -14.3%	N/A	+77.8%	$19.90M	$1.90M	N/A	30	News Coverage Negative News Gap Down
DWTX Dogwood Therapeutics	2.3913 of 5 stars	$2.49 -5.3%	$12.00 +381.9%	-54.2%	$84.64M	N/A	N/A	5	Analyst Forecast Short Interest Decrease
ZYBT Zhengye Biotechnology	0.1307 of 5 stars	$1.64 -0.6%	N/A	-79.5%	$77.72M	$16.64M	N/A	278	Positive News
LONA Athira Pharma	3.53 of 5 stars	$7.90 +4.0%	$17.33 +119.5%	N/A	$76.00M	N/A	N/A	40	News Coverage
CING Cingulate	2.7229 of 5 stars	$5.22 +2.1%	$27.00 +417.7%	+34.6%	$75.51M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. DWTX, ZYBT, LONA, CING, and SPRO

How does Cyclerion Therapeutics compare to Dogwood Therapeutics?

Summary

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Summary

How does Cyclerion Therapeutics compare to Athira Pharma?

Summary

How does Cyclerion Therapeutics compare to Cingulate?

Summary

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. DWTX, ZYBT, LONA, CING, and SPRO

How does Cyclerion Therapeutics compare to Dogwood Therapeutics?

Do insiders & institutionals believe in DWTX or CYCN?

Does the media favor DWTX or CYCN?

Is DWTX or CYCN more profitable?

Which has higher valuation & earnings, DWTX or CYCN?

Which has more risk and volatility, DWTX or CYCN?

Do analysts recommend DWTX or CYCN?

Summary

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Which has more volatility and risk, CYCN or ZYBT?

Does the media refer more to CYCN or ZYBT?

Do analysts rate CYCN or ZYBT?

Do institutionals & insiders have more ownership in CYCN or ZYBT?

Is CYCN or ZYBT more profitable?

Which has better earnings and valuation, CYCN or ZYBT?

Summary

How does Cyclerion Therapeutics compare to Athira Pharma?

Does the media prefer LONA or CYCN?

Which has preferable earnings & valuation, LONA or CYCN?

Is LONA or CYCN more profitable?

Which has more risk and volatility, LONA or CYCN?

Do insiders and institutionals believe in LONA or CYCN?

Do analysts prefer LONA or CYCN?

Summary

How does Cyclerion Therapeutics compare to Cingulate?

Do institutionals & insiders believe in CING or CYCN?

Does the media prefer CING or CYCN?

Do analysts prefer CING or CYCN?

Which has stronger valuation & earnings, CING or CYCN?

Which has more risk & volatility, CING or CYCN?

Is CING or CYCN more profitable?

Summary

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Do insiders and institutionals believe in SPRO or CYCN?

Is SPRO or CYCN more profitable?

Do analysts prefer SPRO or CYCN?

Which has preferable earnings & valuation, SPRO or CYCN?

Which has more volatility and risk, SPRO or CYCN?

Does the media favor SPRO or CYCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools